The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.
 
George R. Blumenschein
Honoraria - Abbvie/Genentech; Bayer; Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Merck
Research Funding - Abbvie; AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; GlaxoSmithKline; Merck; Novartis; Xcovery
 
Agathe Bourgogne
Employment - Immatics
 
Carsten Reinhardt
Employment - Immatics
Leadership - Immatics
Stock and Other Ownership Interests - Immatics
 
Hong Ma
Employment - Immatics
 
Steffen Walter
Employment - Immatics
Leadership - Immatics
Stock and Other Ownership Interests - Immatics
 
Toni Weinschenk
Employment - Immatics
Leadership - Immatics
Stock and Other Ownership Interests - Immatics
 
Partow Kebriaei
No Relationships to Disclose
 
Patrick Hwu
Stock and Other Ownership Interests - Immatics; Iovance Biotherapeutics
Consulting or Advisory Role - Dragonfly Therapeutics; GlaxoSmithKline; Immatics; Iovance Biotherapeutics; Sanofi
Research Funding - Genentech (Inst)
 
Harpreet Singh
Employment - Immatics
Leadership - Immatics
Stock and Other Ownership Interests - Immatics